Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set to report its Q4 2025 earnings on Jan. 30. Wall Street analysts expect the company to post EPS of $3.36, up from $2.16 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $16.39 billion, up from $15.10 billion a year earlier. Don't Mi ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - The article discusses AbbVie (ABBV) and highlights its strong buy potential due to the expansion of Rinvoq and the addition of its immunology pipeline [2]. Company Overview - AbbVie is positioned favorably in the biotech sector, with a focus on long-term value generation through its healthcare investments [2]. Analyst Background - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis and a model portfolio of small and mid-cap stocks [2].

Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Dec. 1, 2025 /PRNewswire/ --Â AbbVie (NYSE: ABBV) today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment of migraine in adults (with or without aura). The study met its primary and key secondary endpoints, with atogepant demonstrating superiority in pain freedom and freedom from most bothersome migraine symptom (MBS) two hou ...

Core Viewpoint - The article highlights three dividend-paying stocks—AbbVie, Home Depot, and ExxonMobil—that have consistently raised their dividends for over a decade, offering yields significantly higher than the S&P 500 average, making them attractive long-term investments. AbbVie - AbbVie currently offers a dividend yield of approximately 2.9%, which is more than double the S&P 500 average of 1.2% [3] - The company has a history of over 50 consecutive years of dividend increases, qualifying it as a Dividend King [3][4] - AbbVie recently raised its dividend by 5.5%, and since its spin-off from Abbott Laboratories, it has increased quarterly dividends by over 330% [4] - For the first nine months of the year, AbbVie reported an 8% increase in sales, totaling $44.5 billion, with Skyrizi and Rinvoq generating $18.5 billion, surpassing Humira's current quarterly sales of $3.3 billion [6][7] Home Depot - Home Depot has raised its dividend for 16 consecutive years, with a more than 50% increase since 2020, currently yielding 2.7% [8] - Despite facing challenges due to decreased discretionary spending, the company anticipates a 3% sales growth for the current fiscal year [9] - Home Depot's shares have declined by 13% this year, but the company is expected to recover in the long term due to its strong position in the home repair market [12] ExxonMobil - ExxonMobil offers the highest yield among the three at 3.5%, with a history of 43 consecutive years of annual dividend growth at an average rate of 5.8% [13][14] - The company has faced earnings volatility, with a decline of $3.7 billion to $22.3 billion this year, but it maintains strong financial health, with earnings per share of $5.16 exceeding its annual dividend payout of $4.12 [14][16] - ExxonMobil's stock has increased by 8% this year and is trading at an estimated 16 times its future earnings, presenting a good value for income investors [16]

I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV, ADP, CTAS, FDS, HRL, JNJ, LOW, NEE, O, PEP, TROW, WST either through stock ownership, opti ...

Buying a dividend stock and forgetting about it isn’t as simple as it sounds, even for seasoned income investors. The market could crash, the income potential might not be worth it, and you might end up thinking that your money is better off somewhere else. That said, the buy-and-forget approach isn’t impossible either. Buy-and-Forget stocks are investors' “core holdings” that they keep forever, regardless of what happens. And today, I came up with three such dividend stocks from the Dividend Kings list t ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC.3 MONT ...

Core Viewpoint - The article highlights eight dividend stocks that cater to various investment styles, emphasizing the importance of balancing current income with long-term growth in a diversified dividend strategy [1][2]. Group 1: Stock Summaries - **American Express (AXP)**: Operates a closed-loop payments network with a yield of 0.87% and a payout ratio of 16%, indicating significant potential for dividend growth due to its affluent customer base and strong pricing power [3][4]. - **JPMorgan Chase (JPM)**: The largest U.S. bank by assets, offering a 2% yield and a 28% payout ratio, making it a solid choice for investors seeking both income and capital appreciation [5]. - **Costco (COST)**: Generates profit primarily from membership fees, with a low yield of 0.5% but a 27% payout ratio and a history of substantial special dividends, showcasing its commitment to shareholder returns [6][7]. - **S&P Global (SPGI)**: Provides essential financial market services with a yield of 0.8% and a 28% payout ratio, boasting a 52-year history of dividend increases, reflecting its strong market position [9]. - **AbbVie (ABBV)**: A biopharmaceutical company with a 3% yield and a remarkable 53 consecutive years of dividend increases, supported by a robust pipeline and strategic acquisitions [10]. - **Pfizer (PFE)**: A major pharmaceutical company with a high yield of 6.7% but a payout ratio near 98%, appealing to income-focused investors despite earnings volatility risks [11]. - **Philip Morris International (PM)**: Offers a 3.8% yield with a payout ratio of nearly 78%, focusing on smoke-free products to differentiate itself and provide growth opportunities [12][13]. - **Nvidia (NVDA)**: A technology company with a minimal yield of 0.02% but a low payout ratio of 1%, indicating strong potential for future dividend growth driven by substantial free cash flow [15].

Core Insights - Pfizer and AbbVie are both leading U.S. pharmaceutical companies with strong positions in various therapeutic areas, with Pfizer's oncology sales accounting for approximately 28% of its total revenues and AbbVie’s immunology drugs contributing around 50% of its net revenues [1][2]. Pfizer (PFE) Overview - Pfizer has strengthened its oncology position with the acquisition of Seagen in 2023, leading to a 7% increase in oncology revenues year-to-date, driven by key drugs [4]. - Non-COVID operational revenues are improving, with a 9% operational increase in recently launched and acquired products in the first nine months of 2025, supporting growth expectations for 2026 [5]. - Pfizer anticipates cost savings of $7.7 billion by the end of 2027 through restructuring and cost reduction efforts, with a dividend yield of around 7% [6]. - The company is expanding its pipeline through acquisitions, including a $10 billion deal for Metsera, which adds significant potential in the obesity market [7]. - Pfizer faces challenges with declining sales of COVID products and expects a significant impact from patent expirations between 2026-2030, estimating a $1 billion unfavorable impact from the Inflation Reduction Act [8][10]. AbbVie (ABBV) Overview - AbbVie has successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [11][12]. - The oncology segment contributed $5.0 billion in revenues, while neuroscience drugs saw a 20.3% increase in sales, totaling almost $7.8 billion [13]. - AbbVie has pursued inorganic growth through over 30 M&A transactions since early 2024, particularly in immunology, while facing near-term challenges from Humira's biosimilars and competitive pressures [14]. - The aesthetics portfolio has seen a 7.4% decline in global sales, impacted by macroeconomic challenges and low consumer sentiment [15]. Financial Estimates and Performance - The Zacks Consensus Estimate for Pfizer's 2025 sales implies a 1.1% decrease, while AbbVie's estimates indicate an 8.1% increase in sales [16]. - Year-to-date, Pfizer's stock has declined by 3.0%, whereas AbbVie's stock has risen by 30.5%, outperforming the industry average of 15.9% [20]. - AbbVie’s dividend yield is 2.8%, compared to Pfizer’s 6.7% [26]. Investment Outlook - Both companies hold a Zacks Rank 3 (Hold), but AbbVie is favored due to its robust growth prospects and lack of significant upcoming loss of exclusivity events [28]. - AbbVie expects to achieve mid-single-digit revenue growth in 2025, driven by the strong performance of Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29].